News-Papers
Testimonial
Video Gallery
Melatonin as an adjuvant to therapeutic prostate cancer vaccines
Published on Friday, 27 March 2015
Letter to the Editor
See also About Melatonin.
Comment on
Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment
Search
Follow us...
Latest
- Molecular and cellular mechanisms of melatonin in breast cancer
- Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review
- Melatonin as an adjuvant treatment modality with doxorubicin
- Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells
- Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines
- Melatonin reduces lipid peroxidation and nitric oxide during irradiation-induced oxidative injury in the rat liver
- Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis
- Melatonin protects rat liver against irradiation-induced oxidative injury
- Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies
- Melatonin alleviates doxorubicin-induced mitochondrial oxidative damage and ferroptosis in cardiomyocytes by regulating YAP expression
- Melatonin inhibits FAK signaling to suppress PD-L1 expression and enhance chemosensitivity in triple-negative breast cancer
- Therapeutic potentials of melatonin in the treatment of lymphoma: A review of current evidence
- Radiomitigation by Melatonin in C57BL/6 Mice: Possible Implications as Adjuvant in Radiotherapy and Chemotherapy
- Targeting growth hormone in cancer: future perspectives
- Tumour-Derived Human Growth Hormone As a Therapeutic Target in Oncology
- Melatonin induces apoptosis and cell cycle arrest in cervical cancer cells via inhibition of NF-κB pathway
- Molecular basis of melatonin protective effects in metastasis: A novel target of melatonin
- GH and IGF1 in cancer therapy resistance
Most Read
- The Di Bella Method (DBM)
- About melatonin - 1996
- All-trans-retinoic acid and cancer
- Biography
- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer
- Chronic Lymphocytic Leukemia: 4 patients, long-lasting remission
- Somatostatin in oncology, the overlooked evidences
- Bibliography
- How effective is chemo therapy?
- Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage
- Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report
- Complete objective response to biological therapy of plurifocal breast carcinoma
- Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report
- Vademecum
- Frequently Asked Questions
- Declaration recommends eliminate the use of Impact factor for research evaluation
- Non–Small-Cell Lung Cancer Patients with Low Performance Status: study on 28 patients
- Breast cancer: study on 122 cases. The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer